ArticleBMJ open2026

Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart).

Apoorva Aiyengar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.